oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. morphic tx is joining a three decade quest led by our scientific founder, tim springer, who initially discovered the integrin receptor family in the 1980s. this receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.
Company profile
Ticker
MORF
Exchange
Website
CEO
Praveen P. Tipirneni
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Morphic Holding, LLC
SEC CIK
Corporate docs
Subsidiaries
Morphic Therapeutic, Inc. • Morphic Security Corporation • Morphic Therapeutic UK Ltd ...
IRS number
473878772
MORF stock data
Latest filings (excl ownership)
8-K
Entry into a Material Definitive Agreement
26 Apr 24
S-3ASR
Automatic shelf registration
26 Apr 24
424B5
Prospectus supplement for primary offering
26 Apr 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
10-Q
2024 Q1
Quarterly report
25 Apr 24
8-K
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
25 Apr 24
8-K
Regulation FD Disclosure
12 Mar 24
S-8
Registration of securities for employees
22 Feb 24
Transcripts
Latest ownership filings
4
Bruce Rogers
28 Mar 24
4
Simon Peter Cooper
19 Mar 24
3
Simon Peter Cooper
19 Mar 24
SC 13G/A
EcoR1 Capital, LLC
15 Feb 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
SC 13G/A
Point72 Asset Management, L.P.
14 Feb 24
SC 13G/A
Artal International S.C.A.
9 Feb 24
SC 13G/A
Polaris Partners VII, L.P.
9 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G
WELLINGTON MANAGEMENT GROUP LLP
8 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 74.79 mm | 74.79 mm | 74.79 mm | 74.79 mm | 74.79 mm | 74.79 mm |
Cash burn (monthly) | 47.68 mm | 894.08 k | 14.92 mm | 12.99 mm | 9.75 mm | 9.07 mm |
Cash used (since last report) | 329.19 mm | 6.17 mm | 102.98 mm | 89.66 mm | 67.31 mm | 62.63 mm |
Cash remaining | -254.39 mm | 68.62 mm | -28.19 mm | -14.86 mm | 7.48 mm | 12.16 mm |
Runway (months of cash) | -5.3 | 76.7 | -1.9 | -1.1 | 0.8 | 1.3 |
Institutional ownership, Q2 2023
96.5% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 161 |
Opened positions | 156 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 2.21 tn |
Total shares | 48.29 mm |
Total puts | 96.90 k |
Total calls | 290.10 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
FMR | 6.87 mm | $394.08 bn |
EcoR1 Capital | 3.85 mm | $220.55 bn |
Timothy A Springer | 2.77 mm | $108.02 mm |
BLK Blackrock | 2.75 mm | $157.59 bn |
Wellington Management | 2.30 mm | $132.08 bn |
T. Rowe Price | 2.19 mm | $124.97 bn |
Artal International S.C.A. | 2.15 mm | $61.86 mm |
Artal | 2.14 mm | $121.98 bn |
Polaris Partners VII | 2.09 mm | $99.06 mm |
Vanguard | 1.91 mm | $109.31 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
27 Mar 24 | Rogers Bruce | Common Stock | Option exercise | Acquire M | No | No | 4.3151 | 7,400 | 31.93 k | 149,883 |
27 Mar 24 | Rogers Bruce | Stock Option (right to buy Common Stock) Common Stock | Option exercise | Dispose M | No | No | 4.3151 | 7,400 | 31.93 k | 74,714 |
18 Mar 24 | Simon Peter Cooper | RSU Common Stock | Grant | Acquire A | No | No | 0 | 7,000 | 0.00 | 7,000 |
18 Mar 24 | Simon Peter Cooper | RSU Common Stock | Grant | Acquire A | No | No | 0 | 14,000 | 0.00 | 14,000 |
18 Mar 24 | Simon Peter Cooper | Employee Stock Options Common Stock | Grant | Acquire A | No | No | 33.46 | 170,000 | 5.69 mm | 170,000 |
16 Jan 24 | DeVaul William | Common Stock | Sell | Dispose S | No | No | 27.4907 | 4,509 | 123.96 k | 23,029 |
16 Jan 24 | Farrell Robert E Jr | Common Stock | Sell | Dispose S | No | No | 27.4907 | 5,089 | 139.90 k | 34,992 |
14 Jan 24 | DeVaul William | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,250 | 0.00 | 27,538 |
14 Jan 24 | DeVaul William | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 3,250 | 0.00 | 6,500 |
14 Jan 24 | Farrell Robert E Jr | Common Stock | Option exercise | Acquire M | No | No | 0 | 3,470 | 0.00 | 40,081 |
Press releases
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2024
25 Apr 24
MORF NEWS: Johnson Fistel has Commenced an Investigation on Behalf of Morphic Holding Company Shareholders
23 Apr 24
Ademi LLP Investigates Claims of Securities Fraud against Morphic Holding, Inc.
2 Apr 24
Morphic Holding, Inc. (MORF) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
26 Mar 24
MORF Investor Notice: Abraham, Fruchter & Twersky, LLP Investigating Claims on Behalf of Investors of Morphic Holding, Inc. (NASDAQ:MORF)
20 Mar 24